NCT00053781 2023-08-04
Perifosine in Treating Patients With Metastatic or Recurrent Malignant Melanoma
Canadian Cancer Trials Group
Phase 2 Completed
Clinical Trials
41 trialsNCT00053794 2023-08-04
Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma
Canadian Cancer Trials Group
Phase 2 Completed
NCT02238496 2023-05-25
Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas
Columbia University
Phase 1 Completed
NCT00590954 2020-10-19
Clinical and Molecular-Metabolic Phase II Trial of Perifosine for Recurrent/Progressive Malignant Gliomas
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00005794 2019-12-13
Perifosine in Treating Patients With Advanced Solid Tumors
University of Wisconsin, Madison
Phase 1 Completed
NCT01048580 2018-06-28
Study of Perifosine + Capecitabine for Colon Cancer Patients
AEterna Zentaris
Phase 1 Completed
NCT00398710 2018-03-15
A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia
AEterna Zentaris
Phase 2 Completed
NCT00847366 2018-03-15
Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma
AEterna Zentaris
Phase NA Completed
NCT00391560 2018-03-14
Phase II Study of Perifosine in Patients With Refractory and Relapsed Leukemia
AEterna Zentaris
Phase 2 Completed
NCT00398879 2018-03-14
Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
AEterna Zentaris
Phase 2 Completed
NCT01224730 2018-03-14
A Food Effect and QTc Study of Perifosine in Patients With Advanced Malignancies
AEterna Zentaris
Phase 1 Completed
NCT00389077 2018-03-07
Trial of Two Schedules of Perifosine for Patients With Solid Tumors or Lymphomas
AEterna Zentaris
Phase 2 Completed
NCT00401388 2018-03-07
A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas
AEterna Zentaris
Phase 2 Completed
NCT00448721 2018-03-01
A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer
AEterna Zentaris
Phase 2 Completed
NCT00375791 2018-02-28
Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma
AEterna Zentaris
Phase 2 Completed
NCT00401011 2018-02-23
Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients
AEterna Zentaris
Phase 1/2 Completed
NCT00399789 2018-02-22
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
AEterna Zentaris
Phase 1/2 Completed
NCT00455559 2018-02-22
Ph II Study of Perifosine Plus Gleevec for Patients With GIST
AEterna Zentaris
Phase 2 Completed
NCT01002248 2018-02-09
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
AEterna Zentaris
Phase 3 Terminated
NCT00498966 2018-02-05
Ph II Study of Perifosine for Patients With Carcinoma of the Kidney
AEterna Zentaris
Phase 2 Completed
NCT00422656 2017-12-26
Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00776867 2017-08-01
Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01049841 2017-03-10
Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00431054 2016-02-19
Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00053924 2015-07-23
Perifosine in Treating Patients With Advanced Pancreatic Cancer
University Health Network, Toronto
Phase 2 Completed
NCT00054145 2015-07-23
Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast Cancer
University Health Network, Toronto
Phase 2 Completed
NCT00019656 2015-04-29
Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00058214 2015-02-23
Perifosine in Treating Patients With Recurrent Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00398814 2014-02-19
Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers
AEterna Zentaris
Phase 1 Completed
NCT00399152 2014-02-19
Perifosine + Sunitinib Malate for Patients With Advanced Cancers
AEterna Zentaris
Phase 1 Completed
NCT00398697 2014-02-13
Phase I Perifosine and Gemcitabine Study
AEterna Zentaris
Phase 1 Completed
NCT00399087 2014-02-13
Phase I Trial of Docetaxel With Perifosine
AEterna Zentaris
Phase 1 Completed
NCT00399126 2014-02-13
Phase I Trial of Paclitaxel With Perifosine
AEterna Zentaris
Phase 1 Completed
NCT00301938 2013-09-30
7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes
National Cancer Institute (NCI)
Phase 1 Completed
NCT01097018 2013-07-02
X-PECT
AEterna Zentaris
Phase 3 Completed
NCT00059982 2013-06-24
Perifosine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00060437 2013-06-19
Perifosine in Treating Patients With Metastatic, Androgen-Independent Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00064324 2013-06-04
Perifosine in Treating Patients With Advanced Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00062387 2013-06-03
Perifosine in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00873457 2013-05-27
Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Duke University
Phase 2 Completed
NCT00415064 2012-07-06
Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma
AEterna Zentaris
Phase 1 Completed